Pure Global Cannabis Inc. (TSXV:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global” or “PURE”), through its subsidiary PureSinse Inc., (“PureSinse”), is pleased to announce that Dr. Sanjeev Goel, a leading physician in medical cannabis has joined the PureSinse team as Chief Medical Officer.

Dr. Goel has a wealth of experience in medical cannabis and a pioneer in medical cannabis since 2015. He provides cutting-edge treatments to patients across the country and has led the formation of two resource centres for medical cannabis that have 3,000 patients registered with licensed producers in Canada. He was also founder and CEO for an integrative medical practice using cutting-edge medical treatments for patients across Canada.


Dr. Goel has been a transformative force in health care, founding a not-for-profit organization dedicated to empowering health care providers to improve patient care by becoming change agents. He also founded a healthcare software company to improve the quality of care physicians can offer their patients that led to the development of the largest primary care patient portal in Canada.

PureSinse looks forward to Dr. Goel serving as an integral member of the leadership team. As Chief Medical Officer, he will provide direction on projects supporting medical cannabis patients, notably the patient care experience and physician education.

“I am so excited to be a part of the Pure Global team. The company is truly focused on innovation in medical cannabis with the aim of helping patients across the globe, and that’s close to my heart.” said Dr. Goel upon joining.

Dr. Goel will act as the lead relationship partner with doctors and medical professionals, using his expertise in healthcare and IT to provide guidance on medical cannabis and systems to enable efficient, accurate patient care.

“I am thrilled to add Dr. Goel to our core team to help deliver patient-focused solutions enabling better education and ultimately improved patient outcomes”, said Malay Panchal, R.Ph., B.Sc.Phm., President & CEO of Pure Global. “Pure has a patient-centric focus and a clear vision for patient care. Dr. Goel’s extensive experience as a practicing physician will allow him to offer advice regarding clinical research projects, strategies to address the needs of wellness customers, and ways to integrate existing and new wellness products. He also brings a wealth of other skills to the organization.”

About Pure Global Cannabis

Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an innovations-based cannabis company led by experienced pharma, biotechnology, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and the Cannabis Act. The company’s Brampton campus will house facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labelled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.

To register to Pure Global’s mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.

FORWARD-LOOKING STATEMENTS

This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Pure Global Cannabis Inc. (TSXV:PURE; OTC: PRCNF; FRA:1QS) for an Investor Presentation.

Source: www.newswire.ca

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed the 2nd and final tranche of its Unit financing. In connection with the closing, the Company issued 1,356,873 Units at a price of $0.55 per Unit, for gross proceeds of $746,280.15. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.25 for a period of 20 consecutive trading days. Finder’s fees of $42,542, 3,200 Finder’s shares and 80,550 Finder’s warrants were issued in connection with finder’s fees payable.

In total, the Company raised gross proceeds of $1,757,180 and issued 3,194,873 Units.

Keep reading... Show less

 Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.

DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press releases dated July 21, 2020 and July 31, 2020, the Company proposes to amend the exercise price of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.

The Company had initially proposed a lower amended price, but that proposal was not approved by the TSX Venture Exchange (“Exchange“), however, the Exchange indicated that a $0.10 exercise price, may be more acceptable. Accordingly, the proposed amendment remains subject to Exchange approval.

Keep reading... Show less

Issuance of U.S. Patent No. 10,851,077 covering methods for extracting and concentrating cannabinoids using ultrasound-enhanced solvent extraction bolsters World Class’ intellectual patent portfolio

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announced the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10,851,077 on December 1, 2020 in relation to the Company’s methods for extracting and concentrating cannabinoids and other target compounds from cannabis using ultrasound-enhanced solvent extraction

Keep reading... Show less

Ubican brings well-known brands and is a trusted vendor with an established sales and marketing program

Chemesis International Inc. (CSE:CSI) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces Ubican Global (“Ubican”) as its primary supplier for its United States VICKI program. Ubican is a trusted supplier of a family of brands, each with multiple types of products. The products include tinctures, digestibles, edibles, pet, beautyskincare, topical, edible, fitness, and smokable products

Keep reading... Show less